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Abstract Biomarkers are of increasing importance for
personalized medicine, with applications including diag-
nosis, prognosis, and selection of targeted therapies. Their
use is extremely diverse, ranging from pharmacodynamics
to treatment monitoring. Following a concise review of
terminology, we provide examples and current applications
of three broad categories of biomarkers—DNA biomark-
ers, DNA tumor biomarkers, and other general biomarkers.
We outline clinical trial phases for identifying and vali-
dating diagnostic and prognostic biomarkers. Predictive
biomarkers, more generally termed companion diagnostic
tests predict treatment response in terms of efficacy and/or
safety. We consider suitability of clinical trial designs for
predictive biomarkers, including a detailed discussion of
validation study designs, with emphasis on interpretation
of study results. We specifically discuss the interpretability
of treatment effects if a large set of DNA biomarker
profiles is available and the number of therapies is identical
to the number of different profiles.
Introduction
Genetic variation contributes to both disease susceptibility
and treatment response. Genome-wide association studies
(GWAs) have enabled rapid discovery of genetic variants
contributing to the pathogenesis of complex genetic dis-
eases (Manolio 2010), as well as detection of many phar-
macogenetic markers (Link et al. 2008; Verschuren et al.
2012). The driving hope of these major advances in genetic
epidemiology is that promotion of personalized medicine
will improve medical decision-making.
Although use of the term personalized medicine is often
limited to the identification of the optimal drug and the
optimal dosage for a subgroup of patients, current person-
alized medicine applications are far more broad, and might
include situations of withholding treatment, preventive
interventions, or targeted treatment options for individual
patients. In prostate cancer, for example, DNA biomarker
tests may be used to determine whether treatment may be
safely delayed for a period of watchful waiting. If the tumor
is demonstrated due to lack of genes causing an aggressive
form of the cancer, it may remain stable for decades, and the
need for radical surgical resection with subsequent radio- or
chemotherapy may be obviated (Kroll 2008). In contrast, in
other instances, genetic profiles may be used to determine
preventive interventions. This approach is already used for
some forms of hereditary cancer, in which individual
genetic testing is the basis for deciding upon specific,
sometimes very radical interventions such as preventive
surgery (Kroll 2008).
Beyond treatment schemes that are applied identically
across large subgroups of patients—to which some authors
have applied the distinct term stratified medicine (Trusheim
et al. 2007)—other personalized medicine applications
offer targeted treatment options for individual patients.
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Anti-inflammatory therapies, for example, such as anti
TNF, anti IL-6, or anti IL-1b, are thought to be effective in
inflammatory diseases, such as Crohn’s disease (Buchner
et al. 2011; Cottone et al. 2010). Other molecules seem
suitable for use as anti-inflammatory therapy as well. To
choose one or a combination of different anti-inflammatory
therapies, the physician might first obtain the genetic profile
of a patient by sequencing. Depending on the individual
DNA profile, the physician might select the anti-inflam-
matory combination therapy, of which there are many.
Though foundational to personalized medicine, biological
markers, biomarkers for short, are diversely defined in the
literature. Gallo et al. (2011) summarize some of the defini-
tions, and observe that the most commonly adopted definition
states that ‘‘a biomarker is any substance or biological
structure that can be measured in the human body and may
influence, explain or predict the incidence or outcome of
disease’’. However, it is a matter of debate whether the
qualification that biomarkers must be measured in the human
body is a reasonable limitation. A related definition has been
given by Gallo et al. (2011) who define ‘‘biomarkers as any
substance, structure or process that can be measured in bio-
specimen and which may be associated with health-related
outcomes’’. From our perspective, this definition is too gen-
eral and should include a specific association with a health or
clinical outcome. Our preference, therefore, is for the defi-
nition developed by the Biomarkers Definitions Working
Group (2001): ‘‘A biomarker is a characteristic that is
objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes or pharmacologic
responses to a therapeutic intervention.’’ Although more than
a decade old, this definition is comprehensive and sufficiently
broad to capture the full range of current biomarker appli-
cations, described in detail in the Table 1.
In personalized medicine, it is necessary to distinguish
between prognostic and predictive biomarkers. Following
Buyse et al. (2011), the difference is that prognostic bio-
markers help in predicting the progress of the disease,
while predictive biomarkers are connected with the
response to a treatment.
Having clarified fundamental terms, we will proceed to a
discussion of similarities and differences of biomarkers,
illustrate current uses of some of these biomarkers, and out-
line specific aspects of diagnostic, prognostic, and predictive
biomarker studies. Finally, we will discuss various study
designs for the validation of predictive biomarkers in detail.
DNA biomarkers, DNA tumor biomarkers, and general
biomarkers
Genetic information, coded within DNA, requires stability
because DNA directs the production of proteins required
for the cell structure and function of cells over a lifetime.
Some authors state that DNA is stable over an individual’s
lifetime (Hicks and Coquoz 2009), and biomarkers
explicitly representing this stability are termed ‘‘DNA
biomarkers’’ in the discussion which follows. Single
nucleotide polymorphisms (SNPs), short tandem repeats
(STRs), deletions, insertions, or other variation on the
DNA sequence level are among this group. Due to the
availability of high-throughput molecular biological facil-
ities, SNPs are the most commonly used type of DNA
variation. In most applications SNPs are diallelic, resulting
in three possible genotypes.
Cancer is a disease that involves changes to the DNA at
the cellular level, and these changes can be measured in the
tumor. Distinct from DNA biomarkers outlined above, we
will use the term ‘‘DNA tumor biomarkers’’ to indicate
biomarkers specific to cancerous tumors. Typically, only
the presence or absence of a mutation in a gene is
determined.
Finally, we use the term ‘‘general biomarkers’’ for all
other forms of biomarkers, such as RNA, protein, or
metabolite measurements which can be measured in bio-
fluid, tissue, or even cell lines. While most general bio-
markers share the property of being quantitative with
positive measurement values, both DNA biomarkers and
DNA tumor markers are discrete in nature (Table 2).
Nevertheless, when used in the diagnostic process, thresh-
olds need to be introduced for all types of biomarkers to
relate biomarker measurements to clinical decision-making.
Important differences between DNA biomarkers and
DNA tumor or general biomarkers stem from the fact that
DNA is stable over the entire lifetime (Table 2). DNA
biomarkers are reproducible, can be measured at any point
in time, and may be used in both prospective and retro-
spective studies. Specifically, DNA biomarkers can be
prospectively validated in biobanks, i.e., in studies, where
clinical information has already been collected. The
authors stress that they would not call such kind of study a
prospective one.
In general, DNA biomarkers are simpler to measure than
DNA tumor or general biomarkers. Sample drawing, han-
dling and storage protocols are generally also simpler for
DNA biomarkers, and laboratory time and cost for mea-
surement is lower. Nevertheless, DNA biomarkers are not
without disadvantages.
First, as they do not vary over lifetime, they cannot be
used for therapy monitoring, pharmacodynamics, or as
surrogate markers. A second general problem is ‘‘durabil-
ity’’, as the rate of discovery of new DNA biomarkers is
frequently more rapid than their product cycles. By the
time, a DNA multimarker test has successfully passed all
steps for marketing approval, including refunding by health
insurance companies, it may already be rendered
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scientifically obsolete by newly discovered DNA bio-
markers with seemingly better performance.
Pertinent differences between DNA tumor biomarkers
and general biomarkers (Table 2) include the fact that
DNA tumor biomarkers generally cannot serve as surrogate
markers—while general biomarkers often can—and the
fact that DNA tumor biomarkers can show greater
variation, depending on how they are measured. If a DNA
tumor biomarker is measured through biopsy, for example,
it is possible for one biopsy probe to be tumor free, while
another contains tumor cells, and this difference may result
in different DNA tumor biomarker results. In contrast, if a
general biomarker is measured, for example, from plasma,
it is generally stable for the time point of measurement.
Table 1 Important terms in biomarker studies
Term Explanation
Biomarker A characteristic that is objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention (Biomarkers Definitions Working Group 2001).
Cancer biomarker A biomarker that is present in tumor tissue or serum and includes many different
molecules, such as DNA, mRNA, or proteins. Tumor biomarkers are measured in
tumor tissue, and tumor DNA biomarkers are measured from tumor tissue.
Clinical endpoint A characteristic or variable that reflects how a patient feels, functions, or survives
(Biomarkers Definitions Working Group 2001).
Companion endpoint A biomarker that is essential to the efficacy and safety of a corresponding therapeutic
product (Food and Drug Administration 2011).
Copy number variant (CNV) biomarker A biomarker of genomic variation in which blocks of DNA are missing or for which
multiple copies exist.
Diagnostic biomarker A biomarker that relates to the diagnosis or severity of disease. The most important
diagnostic biomarkers are screening biomarkers.
Disease biomarker A biomarker that relates to a clinical endpoint or measure of disease (Kroll 2008).
DNA biomarker A germline biomarker, such as SNPs, STRs, deletions, insertions, or other variation on
the DNA sequence level.
Efficacy biomarker A biomarker that predicts a beneficial effect of a given treatment (Kroll 2008).
Epigenetic biomarker A biomarker that measures epigenetic alterations, such as DNA methylation, histone
methylation, histone acetylation, microRNAs, or other non-coding RNA (Bock 2009).
Monitoring biomarker A biomarker to monitor efficacy or side effects of a drug treatment.
Prognostic biomarker A biomarker that predicts the likely course of disease in a defined clinical population
under standard treatment conditions.
Prediction model A predictive test including multiple markers.
Predictive biomarker A biomarker that forecasts the likely response to treatment (Buyse et al. 2011).
Treatment response may be measured either as efficacy or as safety.
Predictive test Two definitions exist in the literature a test of test of probability for an individual to
develop a disease; alternatively, a test which discriminates between individuals who
will develop a disease and those who will not (Janssens and van Duijn 2008).
Risk prediction The generation or validation of models which make a prognosis for developing a
disease or the prognosis for attaining a clinical endpoint.
Safety biomarker A biomarker that indicates adverse response to a treatment (Sistare et al. 2010).
Toxicity biomarkers are special cases of safety biomarkers.
Screening biomarker A biomarker to discriminate between healthy individuals and those in an early stage of
the disease (Kroll 2008), ideally while subjects are asymptomatic.
Staging biomarker A biomarker that distinguishes between different stages of chronic disease (Kroll 2008).
Stratification biomarker See predictive biomarker.
Surrogate biomarker A biomarker that is regarded as a valid substitute for a clinical endpoint. A surrogate
endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm)
(Biomarkers Definitions Working Group 2001; Kroll 2008).
Target biomarker A biomarker that reports interaction of the drug with its target (Kroll 2008).
Toxicity biomarker A biomarker that reports to the toxic effect of a drug on an in vitro or in vivo system
(Kroll 2008).
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Examples for current use of biomarkers
In this section, we illustrate current applications of bio-
markers for diagnosis, prognosis, and prediction in per-
sonalized medicine. Details of the examples outlined in this
section are provided in Table 3, together with additional
examples of general biomarkers, and in particular, DNA
biomarkers and DNA tumor biomarkers, in current use.
Diagnostic biomarkers are biomarkers used to determine
the diagnosis or severity of a disease. The most important
within this group are screening biomarkers (Table 1),
which are used to discriminate between healthy individuals
and those in an early stage of a disease. For example, the
commercially available point-of-care tests (POCT)
Rheuma-Chec and CCPoint, test serum for antibodies to
mutated citrullinated vitmentin (MCV) or citrullinated
peptides/proteins (anti-CCP antibodies), in order to screen
for rheumatoid arthritis in non-symptomatic, healthy per-
sons (Egerer et al. 2009).
If a diagnosis is known, prognostic biomarkers help to
predict the likely course of disease in a defined clinical
population under standard treatment conditions. For exam-
ple, MammaPrint, a DNA tumor biomarker for breast can-
cer prognosis is used following surgery to indicate whether
risk of metastasis is low or high, and guide physicians to
determine the best kind of treatment for the individual patient.
Such therapy guidance requires the validation of the predic-
tive capability of the biomarker. In fact, in the United States,
MammaPrint is cleared by the Food and Drug Administra-
tion (FDA) as an in vitro diagnostic multivariate index assay
(IVDMIA) (Slodkowska and Ross 2009). In Germany, as of
2012, some health insurance companies will pay the cost of
the test for particular cases.
Predictive biomarkers predict the likely response of a
patient to a special treatment in terms of efficacy and/or
safety and thus support clinical decision-making (Table 1).
For example, GWAs conducted by three independent
groups from North America, Australia/Northern Europe,
and Japan (Holmes et al. 2011) demonstrated that the
IL28B gene is a strong indicator for response to standard
treatment in patients with hepatitis C virus-1 (HCV-1)
infection. Further, there is evidence for population strati-
fication in the IL28B gene, such that treatment response
varied across different ethnic groups. Specifically, Cauca-
sians with the ‘‘good response’’ genotype were more likely
to benefit from treatment. This fact is also mentioned in a
Provisional Guidance for the treatment of HCV (Thomas
et al. 2012), which notes that treatment with special
inhibitors is expected to be less efficacious in persons with
the ‘‘non-response’’ genotype, or African ancestry.
Table 2 Differences between DNA biomarkers, DNA tumor biomarkers, and general biomarkers
Characteristic DNA biomarker DNA tumor biomarker General biomarker
Level of measurement Discrete. In SNPs, one of three
different genotypes is observed
per subject, in general
Discrete. In general, the
measurement is whether a
specific gene is mutated or not
Continuous. RNA, protein, and
metabolite concentrations may take
almost any continuous positive value
Stability, reproducibility Yes Not necessarily as different
mutations may be present in
different parts of the tumor







Suitable as surrogate marker No No, in general Yes
Complexity of measurement Low High High
Time required for
measurement (includes
drawing and preparation of
sample)
Low High High
Time of measurement Does not have to be specified Needs to be specified in
advance




‘‘Durability’’ of the final
biomarker test
Short- to long-term; multimarker
sets may be already obsolete at
start of prospective study
Mid-term to long-term Mid-term to long-term
Study design Retrospective or prospective Prospective only Prospective only
DNA biomarkers are generally measured in the blood, tumor DNA biomarkers are measured in tumor tissue, general biomarkers may be
measured in biofluid, tissue, or cell lines
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While some biomarkers have already been approved by
the FDA, the use of others has been recommended in
clinical guidelines such as the Provisional Clinical Opinion
from the American Society of Clinical Oncology (ASCO),
which publishes clinical direction based on potentially
practice-changing data from major studies. A recent
example of this is a test for epidermal growth factor
receptor (EGFR) mutation in patients with advanced non-
small-cell lung cancer, which determines whether or not
the first-line EGR tyrosine kinase inhibitor therapy is
indicated (Keedy et al. 2011).
Phases of diagnostic biomarker studies
The four different phases in the drug development process
are generally always fixed. Regulatory approval is required
before a new drug can enter the market. In the preclinical
program, safety, pharmacology and pharmacodynamics are
investigated in animal models. The first three clinical
phases establish pharmacokinetics, pharmacodynamics, the
required dose, clinical efficacy and benefit/risk. Following
marketing approval, effects on morbidity and mortality
endpoints, or relative effectiveness are investigated in the
fourth phase (European Medicines Agency 1998b).
Development programs of diagnostic tests undergo a
similar process (European Medicines Agency 2009). In
phase I, it must be demonstrated that the diagnostic test
may be safely applied to humans, and that the technical
properties are well understood, such as mode of applica-
tion, reproducibility, etc. In phase II, the test is applied to
individuals known to be either diseased or ‘‘healthy’’, in
order to obtain initial estimates of sensitivity and speci-
ficity. Phase III studies are the so-called validation studies,
in which the diagnostic test and subsequent diagnostic
workup is carried out in the same manner and setting as it
would be in later clinical and diagnostic practice. Finally,
phase IV diagnostic studies are performed to investigate
Table 3 Examples for biomarkers in current use
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EGFR epidermal growth factor receptor, EGFR TKI EGFR tyrosine kinase inhibitor, ER estrogen receptor, HER2 hormone receptor, K-RAS
Kirsten rat sarcoma viral oncogene homolog, PCO provisional clinical opinion of the American Society of Clinical Oncology
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whether the application of the test leads to a measurable
improvement of the clinical outcome in a broader
population.
This phase concept is oriented towards marketing
approval of diagnostic agents that are intended for in vivo
administration, such as radiopharmaceuticals or contrast
agents for use in imaging techniques, such as magnetic
resonance imaging. In our own projects, we have found an
extended phase approach, summarized in Table 4, to be
more helpful from a developmental perspective for diag-
nostic or prognostic biomarkers (compare the phase models
of Pepe 2003, p. 215, Pepe et al. 2001, Baker et al. 2006,
and Riley et al. 2009).
In phase I of this extended approach, we delineate three
distinct sub-phases: discovery (Ia), assay development and
validation (Ib), and retrospective validation (Ic). The dis-
covery study (phase Ia) is typically performed using high-
throughput technologies. For DNA biomarkers, the dis-
covery phase might be a GWAs, a genome-wide meta-
analysis or even a whole genome sequencing study. In
proteomics, this discovery phase might consist of expres-
sion clone arrays containing tens of thousands of recom-
binant human proteins (for a recent application to prostate
cancer, see Massoner et al. 2012) or multiplex protein
antigen analysis on a Luminex platform (Linkov et al.
2009).
The high-throughput arrays or whole genome sequences
will not be the final product for the diagnostic test to be
released on the market. Therefore, in phase Ib the identified
biomarkers are adapted to a laboratory setting which might
be integrated into clinical routine. The complementary
technology introduced in this phase is generally more
reliable and precise, i.e., its coefficient of variation is lower
and typically has reduced bias. For DNA biomarkers, this
phase combines assay transfer with a better-suited
laboratory platform and the choice of the DNA
marker(s) to be typed on this platform. In proteomics, this
might represent the development of an ELISA, such as the
ELISA for AGR2 in voided urine for detecting secreted
prostate cancer (Wayner et al. 2011).
Following the discovery phase and the change in the
specific laboratory technology, a first retrospective vali-
dation is generally performed (phase Ic) to determine
whether the results from the imprecise high-throughput
technology still hold true. It is important to note that the
sample size in this first retrospective validation is higher
than in the initial high-throughput search (Table 4, last
column).
Subsequent to retrospective validation, multimarker
models are developed, either as part of phase Ic, with the
initial cohort of patients, or as part of phase II, in a retro-
spective study using patients different from those of phase
I. Whether initially developed in phase I or II, this model
will always undergo refinement with the second group of
patients. Nevertheless, a prospective investigation in phase
III may also often be necessary to obtain reliable estimators
for sensitivity and specificity of DNA biomarker tests, or,
for prognostic biomarkers, to attain reliable estimates of
the prognosis, e.g., through the use of Brier scores.
To assess the impact of the diagnostic DNA biomarker
on patient management, a randomized controlled trial is
conducted (in phase IVa), following marketing approval
demonstrating that treating doctors’ knowledge of the test
result improves patient outcome. This phase mimics the
development of a predictive biomarker (see next section).
Finally, health economics studies may be carried out in
order to assess cost-effectiveness of the diagnostic test
(phase IVb).
A challenging element of this extended phase model
for diagnostic and prognostic biomarkers is the term
Table 4 Phases of diagnostic or prognostic biomarker studies
Phase Diagnostic and prognostic biomarkers Typical sample sizes
Description Aim of study
Ia Discovery Identification of promising biomarkers 10–100
Ib Assay development,
assay validation










Validation of early detection properties of biomarker (set); development




Determination of diagnostic accuracy (sensitivity, specificity) in the




Quantification of effect of making the biomarker information available to




Quantification of cost-effectiveness Strongly depends on clinical
consideration of clinical risk
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‘‘prospective validation’’ for phase III. Because germline
DNA is assumed to be stable, the prospective investigation
of an assay in an already ascertained biobank may be
considered to be prospective. However, it must be defini-
tively demonstrated that the biobank has not been used
before, because multiple testing will arise if a biobank is
used for biomarker validation more than once. Proper
definition of standards as to when biobanks may be used
for prospective validation of DNA biomarkers is complex.
The situation becomes even more complex when consid-
ering DNA tumor biomarkers or general biomarkers, as
these biomarkers may change over time such that the time
point of sample drawing may also be crucial. Furthermore,
different sample handling and storage protocols as well as
age of samples may have an effect not only on biomarker
quality but also on biomarker levels (Table 2).
Irrespective of the phase model used (for other alter-
natives, see, e.g., Zhou et al. 2001, p. 61), assay sensitiv-
ity—the technical and analytical validity of the
biomarkers—is a mandatory requirement. Given high assay
sensitivity, the problem of missing values can be ignored
because they are assumed to occur only due to random
technical failure and not any systematic process.
Validation of predictive biomarkers used as companion
tests
As outlined in Sect. ‘‘Examples for current use of biomark-
ers’’, above, and detailed in Table 3, a number of biomarkers
have recently been identified to predict treatment outcome,
and some have proven particularly effective in resolving
unconvincing or ambiguous clinical trial results. For exam-
ple, in the multicenter IPASS (Iressa Pan-Asia Study) trial of
advanced non-small cell lung cancer (NSCLC), patients
treated with either gefitinib or carboplatin plus paclitaxel,
progression-free survival curves of both treatment groups
crossed in the general population of patients (1,200 previ-
ously untreated East-Asian non-smokers or former light
smokers). When treatment groups were stratified for tumors
bearing epidermal growth factor receptor gene (EFGR)
mutation, however, important differences emerged: EGFR-
positive patients’ progression-free survival was consistently
longer in the gefinitab treatment group, while EGFR-nega-
tive patients’ progression-free survival was longer in the
carboplatin–paclitaxel group (Mok et al. 2009). As noted in
Sect. ‘‘Examples for current use of biomarkers’’, the strength
of the relationship was sufficiently compelling that the
American Society for Clinical Oncology has since recom-
mended that patients with NSCLC should have their tumors
tested for EGFR mutations to determine the most appropriate
first-line therapy (Keedy et al. 2011).
In most instances these biomarkers have been identified
after the conduct of phase III trials that were intended to
provide the pivotal evidence about efficacy and positive
benefit/risk of an experimental treatment required to justify
market approval. An important consequence of the retro-
spective nature of these investigations was that the appro-
priateness of the biomarker validation had to be assessed
on a case-by-case basis.
In July 2011, the FDA issued a draft guidance for
industry for ‘‘in vitro companion diagnostic devices’’,
which are predictive biomarkers essential for safe and
effective use of a corresponding therapeutic product (Food
and Drug Administration 2011). The draft guidance
anticipated three uses of companion diagnostics:
1. Identification of patients most likely to benefit from a
particular therapeutic product;
2. Identification of patients likely to be at increased risk
for adverse reactions to a therapeutic product, and;
3. Monitoring treatment response to adjust treatment in
order to improve efficacy and safety.
If either treatment effect or tolerability differs with
respect to the companion diagnostic, the diagnostic test can
be used to refine the patient population. DNA biomarkers
and DNA tumor biomarkers cannot be used for treatment
monitoring for obvious reasons. However, they can be used
for aspects 1 and 2.
The FDA guideline suggests that because companion
diagnostics provide critical information for the appropriate
use of drugs, they require validation as part of the evalu-
ation of efficacy of the experimental treatments, and
information about the diagnostic is reflected in the drugs’
labeling. The use of biobanks for prospective validation,
therefore, might play a role for already approved drugs, if
biomaterial allows systematic investigations into improved
efficacy or safety in biomarker-defined subgroups. Within
the pharmaceutical industry, such research will become
increasingly important to pharmacovigilance and post-
marketing surveillance of drug use. Valid conclusions are,
however, not possible if material for genotyping is avail-
able for only so-called convenience samples (Wang et al.
2010).
At the end of the development program, clinical data
should substantiate that efficacy and/or benefit/risk of the
experimental treatment as compared to control is substan-
tially larger in patients who test positive with the com-
panion diagnostic test than in those who test negative. If
the experimental treatment shows comparable positive
effects in test-negative patients and in test-positive
patients, the diagnostic test would not be required, and the
new treatment might simply be provided to all patients.
Thus, diagnostic tests are only of value if clinical data or
Hum Genet (2012) 131:1627–1638 1633
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ethical reasons support that treatment be withheld in test-
negative patients.
In the context of clarifying specific circumstances in
which a new drug might be used appropriately, infor-
mation from test-negative patients must be available in
order to justify population refinement, and the costs that
use of the biomarker prior to treatment will incur on the
health insurance system. It may be a matter of debate, or
even discriminative power of the companion biomarker,
whether this information might be obtained from a phase
II clinical trial, or whether it should be obtained from
the same trial used to demonstrate efficacy of the
experimental treatment. Obviously, there is no need to
demonstrate in statistical terms that the experimental
treatment does not have advantages over control in test-
negative patients. However, if in the same trial there is
no clear trend towards superior efficacy or improved
benefit/risk, especially in a phase II trial of limited size,
the usefulness of the companion biomarker might be
questioned.
Official regulatory guidance about appropriate study
designs to validate companion diagnostics together with
new drugs is still sparse, although both the FDA and
European Medicines Agency (EMA) have established
procedures, in which applicants may negotiate the amount
of evidence required for marketing authorization in this
setting (European Medicines Agency 2012).
Study designs for predictive biomarkers
Pioneering work on clinical trial designs for predictive
biomarker validation has been performed by Sargent et al.
(2005), Mandrekar and Sargent (2009a, b). More recently,
Buyse et al. (2011), in their seminal review, discuss 10
different study designs for co-development of an experi-
mental drug and a companion diagnostic test.
In selection designs, patients are first tested with the
companion test. Only test-positive patients are then ran-
domized to treatment or control (Fig. 1c). As Buyse et al.
(2011) observe, although these selection designs provide
clear information about treatment efficacy, they fall short
in substantiating the usefulness of the companion test, as
they do not demonstrate lack of benefit in marker-negative
patients. As soon as a test incurs costs, its usefulness for
application should be quantified, and for this a selection
design is only of limited value.
In the interaction or biomarker-stratified design
(Fig. 1b), patients are first tested for the biomarker, and
then randomized to treatment or control with stratification
by the companion biomarker’s test result. This study design
might be considered the gold-standard design for providing
a sound basis for decision-making about the efficacy and
benefit/risk of the experimental drug and the ability of the
companion diagnostic to identify the appropriate patient
population to be treated.
Fig. 1 Common study designs for biomarker studies. a Traditional
randomized-control design where the randomization (R) to standard
(STD) or experimental (EXP) therapy is independent from the results
of the biomarker test. A retrospective evaluation of this design is
possible for DNA biomarkers. b So-called ‘‘Gold standard’’ design.
Randomization to STD or EXP is performed in the total patient
population stratified by the result of the biomarker results.
c Restricted design. To reduce effort, only biomarker-positive patients
are randomized to STD or EXP. Claims about the utility of a
biomarker cannot be made from this trial alone. d Patients are
randomized according to treatment based on biomarker or non-
biomarker-dependent strategy. This is the most flexible design that
provides information about specific individualized treatment rules
according to, e.g., a DNA profile
1634 Hum Genet (2012) 131:1627–1638
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The interaction design allows for several hierarchical
statistical testing procedures. The significance of the
interaction test for the treatment effect in the test-positive
and test-negative stratum may serve as a yardstick for the
usefulness of the companion biomarker. If the interaction
effect is significant, treatment effects in test-positive and
test-negative patients differ; this difference alone does,
however, not in itself assure the utility of a companion
diagnostic. A small but significant treatment effect in test
negatives, even if less marked than the effect in the bio-
marker-positive population, might still be of clinical
importance.
Similarly, if the treatment effect in the larger population
is small and irrelevant, the subgroup of biomarker-positive
patients might be too small to achieve sufficient power in
the interaction test. Evaluation of efficacy and benefit/risk
should always consider the size of the estimated treatment
effect as well.
Adaptive study designs offer a promising means to stop
recruitment for futility in test-negative patients as soon as
sufficient evidence about lack of efficacy in this subgroup
is available. Strategies based on conditional power may be
used to formalize adaptive study designs to some extent
(Lachin 2005; Proschan and Hunsberger 1995; Scha¨fer
et al. 2006). However, in the end, the assessment of the
treatment effect size and the extent of benefit/risk must be
set into perspective.
In instances where no gold standard are available, the
utility of a diagnostic test may be evaluated by com-
paring biomarker-guided treatment with the standard,
non-biomarker-based treatment selection. A highly sim-
plified version of this is depicted in Fig. 1c with only
two profiles and two treatments in the biomarker-guided
treatment group. Again, significant differences between
the outcome in the biomarker-guided and the conven-
tional treatment group may be difficult to achieve and
may fall short in demonstrating the efficacy of the
experimental biomarker.
The individual profile design, which includes a large
number of different profiles leading to the selection of
one out of a large number of different treatments, is
easily validated if it is planned and understood as a
strategic trial comparing conventional treatment selection
to an individualized decision rule (Fig. 1d). Even more
complex approaches can be imagined. For example, an
individualized therapy might combine several monother-
apies, each selected based on the presence or absence of
a specific DNA variant. Such designs and treatment
plans reflect the paradigm of individualized treatment
and personalized medicine. However, they pose new
challenges to the regulatory system, requiring that the
precise particularities of the application of drugs as
mono-therapy, or in combination are well understood and
substantiated with clinical trials data. Obviously, there is
a gap between the validation of the biomarker-based
treatment selection rule and the efficacy of the individual
treatments to be applied based on a complex decision
rule. Consideration needs to be given to the question of
how this gap can be filled.
For example, the global statistics may demonstrate
superiority of the individualized treatment selection when
compared to the current standard. At the same time, some
of the individual treatment combinations may seem to be
inferior to the current standard. Here, it is clear that an
upfront discussion is required to formulate the circum-
stances under which such inconsistencies can be ignored
and under which the overall validity of conclusions has to
be questioned.
Similarly, none of the many investigated treatments or
treatment combinations may provide sufficient clinical
information enabling the assessment of the safety of the
suggested combination therapy in the way this is done in
the standard drug development process, and we acknowl-
edge that this standard process is justified by historical
fallacies. Unless clear evidence is available that all drugs
under investigation are safe and can be combined freely, a
substantial amount of clinical data needs to be provided for
each of the recommended treatments and treatment com-
binations. At least a basic assessment of safety is required
because safety or benefit/risk may be different for different
subpopulations identified with the biomarker rule. Along
the line of the FDA definition of a companion test such
information is a pre-requisite to use a complex decision
rule in patient management. Of course, sample-size
requirements will substantially increase with the number of
treatments and treatment combinations under investigation,
and the IPASS trial can be considered as a model for this.
In some instances, biomarkers may be investigated that
are closely related to the mechanism of action of the
companion drug, and in these instances it may be possible
to provide the required information about the usefulness of
the companion test as early as phase II drug development.
In most instances, however, the traditional design—ran-
domizing patients to treatment and control irrespective of
biomarker outcome—may still be the optimal approach,
such that overall superiority of a drug should first be
demonstrated, subgroups defined by the companion test
excluded from the labeling in retrospect, following the
precautionary principle that harm does not need to be
proven (Fig. 1a).
The credibility of this concept depends on the degree of
independent validation that can be found in the different
studies during the development program and the com-
pleteness of the sampling in every study. Convenience
sampling in subpopulations of poorly defined origin should
be avoided (Wang et al. 2010).
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Discussion
The three pillars of a physician’s work are diagnosis,
therapy, and prognosis. Biomarkers form the basis for all
aspects of personalized medicine, from ‘‘What does the
patient have?’’ (diagnosis) to ‘‘What can the patient do
about it?’’ (therapy) to ‘‘How bad is it?’’ (prognosis).
Although the characteristics and applications of DNA
biomarkers, DNA tumor biomarkers and general bio-
markers differ substantially, the underlying methodological
principles to validate each for use in clinical routine are
identical.
DNA biomarkers are distinct from general biomarkers in
several ways, such as protein expression levels, gene
expression levels or even epigenetic biomarkers. Further,
since germline DNA does not change over time, some
studies utilizing biobanks may be interpreted as prospec-
tive biomarker studies under very special conditions.
However, the critical aspect prior to marketing approval of
a biomarker is how ‘‘convincing evidence’’ may be
achieved and when it has been achieved. Novel strategies
must be developed so that a biomarker assessed in bio-
banks can be considered validated, in particular if biobanks
are to be used multiple times.
An important aspect of biobank biomarker studies is the
transparency of the approach, which directly relates to the
quality of reporting. In general, to date, reporting of bio-
marker studies has been weak. In a systematic review of
studies published between 2004 and 2006, Fontela et al.
(2009) evaluated diagnostic studies that used commercially
available test kits for tuberculosis, HIV, and malaria, and
found that all of the 238 articles fulfilling the study
inclusion criteria had design issues. In only 10 % of the
studies the reference standard was adequately described.
Nine of the 25 indicators of the standards for Reporting of
Diagnostic Accuracy (STARD) (Bossuyt et al. 2004) were
reported in fewer than 25 % of the studies, even though the
studies reviewed were published immediately following
publication of the STARD statement. As Plint et al. (2006)
have effectively demonstrated for therapeutic studies, if
reporting guidelines are adopted by journals, and in con-
sequence by authors, the quality of reporting is measurably
improved. In addition, it is substantially simpler to read
articles if authors follow reporting statements. Therefore,
authors of biomarker studies are strongly encouraged to
report their work using appropriate reporting guidelines,
such as STARD, strengthening the reporting of observa-
tional studies in epidemiology–molecular epidemiology
(STROBE-ME; Gallo et al. 2011), reporting recommen-
dations for tumor marker prognostic studies (REMARK;
McShane et al. 2005), reporting recommendations for
OMICS studies (QUADOMICS; Parker et al. 2010) or the
preferred reporting items for systematic reviews and meta-
analyses (PRISMA, formerly QUORUM; Moher et al.
2009); for a complete list, the reader may refer to the
Equator Network at http://equator-network.org.
While validation of diagnostic and prognostic bio-
markers does not need to be linked to a specific therapy but
rather to standard of care, validation of predictive bio-
markers must be closely linked to the specific therapy
under consideration.
In order to gain marketing approval, pivotal drug trials,
i.e., randomized controlled phase III clinical trials gener-
ally operate from the paradigm recruiting a broad spectrum
of patients, not only to achieve higher enrollment numbers,
but also to investigate the generalizability of findings. If,
however, a drug has different levels of efficacy and safety
in different ethnicities, as in for example gemcitabine,
tamoxifen (Sai and Saito 2011) or warfarin (El Rouby et al.
2004), it might be possible to leverage the power to detect
efficacy and demonstrate safety of a drug as a rationale to
conduct trials in ethnically homogenous populations.
Although the ICH E5 guideline (European Medicines
Agency 1998a) clearly outlines a framework to evaluate
the impact of ethnic factors, the use of an ethnically
homogeneous population to evaluate the effect of a bio-
marker might be more promising if the aim is detection of
different effects between biomarkers (see the study of Link
et al. 2008). If recruitment is done on a global level in
a phase III clinical trial, one has to expect substantial
population stratification, i.e., heterogeneity in the patient
population, and as sample sizes per ethnic group are
eventually small, identification of biomarkers might be
hindered.
Even if a biomarker or a set of biomarkers has been
identified to be a good diagnostic, prognostic, or predictive
marker, application to clinical routine is not certain.
Although predictive biomarkers may be readily applied, as
specific therapies rely on biomarker results, clinical
applications for diagnostic or prognostic biomarkers are
more complex. Here, use in clinical routine will depend on
the ease of applicability, including the media for biomarker
measurement, and whether clinicians can measure the
biomarker in their own laboratory, a local laboratory, or a
specialized laboratory at some distance from their prac-
tices. Also important is the algorithm for obtaining the
decision or a recommendation (Kruppa et al. 2012). If
clinicians are able to perform calculations by hand and the
rules are easy to interpret, acceptance of the biomarker(s) is
more likely than if some kind of ‘‘black box’’ is required.
Therefore, classifications and probabilities estimated by a
logistic regression model are more likely to be accepted by
clinicians than results obtained by machine learning
methods, such as artificial neural networks or support
vector machines—although these generally may look quite
impressive.
1636 Hum Genet (2012) 131:1627–1638
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We conclude that a priori planning of research strategies
is vital for the identification and validation of biomarkers.
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